Franklin Lakes-based BD (Becton, Dickinson and Co.) said July 12 it selected two directors for its diabetes care spinoff company, NewCo.
David Melcher will be non-executive chair of the board of directors, and Dr. Claire Pomeroy will be a director. Their appointments will be effective upon completion of BD’s NewCo spinoff, which is expected to occur in the first half of calendar year 2022.
Additional appointments are expected to be announced prior to that date.
Polen
“Our focus is on setting NewCo on the path to success and growth,” said Tom Polen, chairman, chief executive officer and president of BD, in a prepared statement. “The selection of David and Claire to the NewCo board of directors will provide significant health care and public company leadership experience for NewCo, which will be critical for the future direction of this standalone business as one of the largest diabetes-focused organizations in the world.”
Melcher, 67, will bring strong executive experience to NewCo, a result of his many years in leadership positions in the defense community and as a former chief executive officer of a NYSE public company. He has extensive experience in spinoffs, having served as the inaugural chief executive at Exelis following its spinoff from ITT. He also has extensive experience and expertise in the areas of domestic and international business, program management, strategy development, finance and information technology.
Dr. Pomeroy, 66, has broad experience in areas of health care delivery, health system administration, higher education, medical research and public health. She will bring important perspectives on patient care services, global health and health policy to the NewCo board of directors.
“David and Claire establish a strong foundation for the NewCo board of directors through their many years of experience and insight from the BD board, and I’m particularly excited to tap into David’s background with spinoffs and Claire’s knowledge of the health care provider community,” said Devdatt (Dev) Kurdikar, future CEO of NewCo. “As we seek to leverage and honor the legacy of BD while standing up a new, focused Diabetes Care company, their knowledge of the organization as it stands today, and the evolving global med tech landscape in which we compete, will prove invaluable.”
